UroGen Pharma Ltd.

Listed Company

URGNCIK 0001668243NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsL3FY ends Dec 31

Period

FY 2025

Revenue

$109.79M

Net Income

$-153.49M

Total Assets

$200.46M

Equity

$-105.47M

Shares Out

48.72M

Op. Cash Flow

$-162.44M

URGN$40.24+161.47% · past yearDBEQ Basic

Daily closing prices

Business

UroGen Pharma Ltd. is a biotechnology company developing and commercializing innovative solutions for urothelial and specialty cancers using its proprietary RTGel reverse-thermal hydrogel technology. The company's approved products are Jelmyto (mitomycin for pyelocalyceal solution) for low-grade upper tract urothelial cancer and Zusduri (mitomycin for intravesical solution) for recurrent low-grade intermediate risk non-muscle invasive bladder cancer, both designed to enable sustained-release drug delivery and chemoablation. The pipeline includes next-generation formulations UGN-103 and UGN-104, the oncolytic virus candidate UGN-501, and previously discontinued UGN-301. The company markets its approved products in the United States through a direct sales team.

Summary from 10-K filed 2026-03-02

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	110	90	83	64	48
Cost of revenue	12	9	9	8	5
Gross profit	97	82	73	57	43
Research and development expenses	67	57	46	53	48
Selling, general and administrative expenses	155	121	93	83	88
Operating loss	−125	−97	−66	−79	−92
Financing on prepaid forward obligation	−19	−23	−22	−22	−17
Interest expense on long-term debt	−15	−13	−15	−8	0
Interest and other income, net	5	9	3	1	212,000
Loss before income taxes	−153	−124	−98	−108	−109
Income tax expense	−78,000	−3	−4	−2	−1
Net Loss	−153	−127	−102	−110	−111
Unrealized income (loss) on investments	−37,000	44,000	119,000	−82,000	−296,000
Comprehensive Loss	−154	−127	−102	−110	−111
Net loss per ordinary share - basic and diluted (in dollars per share)	−3.19	−2.96	−3.55	−4.81	−4.96
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)	48	43	29	23	22

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	111	172	95	55	44
Marketable securities	10	65	42	45	45
Restricted cash	1	1	821,000	813,000	1
Accounts receivable, net	33	20	15	13	12
Inventories	16	9	6	4	5
Prepaid expenses and other current assets	15	9	10	11	7
Total current assets	186	276	169	129	114
Property and equipment, net	637,000	655,000	689,000	1	2
Restricted deposit	177,000	176,000	225,000	223,000	223,000
Right-of-Use Assets, Operating and Finance Leases	8	3	2	—	—
Marketable securities	0	5	5	0	675,000
Other non-current assets	5	589,000	2	3	1
Total Assets	200	286	178	136	120
Accounts payable and accrued expenses	28	27	17	12	12
Employee related accrued expenses	14	11	11	8	7
Other Liabilities, Current	5	8	4	3	3
Total current liabilities:	46	46	31	24	22
Prepaid forward obligation	127	121	110	99	86
Long-term debt	122	122	99	98	0
Lease, Liabilities, Noncurrent	6	2	844,000	—	—
Uncertain tax positions liability	4	4	3	3	3
Total Liabilities	306	295	244	225	111
Commitments and Contingencies (Note 20)	—	—	—	—	—
Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at December 31, 2025 and 2024; 48,350,272 and 42,231,746 shares issued and outstanding as of December 31, 2025 and 2024, respectively	133,000	115,000	89,000	63,000	61,000
Additional paid-in capital	854	797	614	488	476
Accumulated deficit	−960	−806	−679	−577	−467
Accumulated other comprehensive income	19,000	56,000	12,000	−107,000	−25,000
Total Shareholders' Deficit	−105	−9	−65	−89	8
Total Liabilities and Shareholders' Deficit	200	286	178	136	120

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	300,000	300,000	800,000	900,000	800,000
Accrued financing on prepaid forward obligation	3	15	12	14	15
Accretion on marketable securities	−2	−3	−1	−498,000	476,000
Share-based compensation	12	13	9	11	23
Amortization (accretion) of discount on long-term debt	476,000	−1	1	2	0
Amortization of right-of-use assets	2	857,000	903,000	893,000	942,000
Acquisitions of IPR&D	3	0	—	—	—
Inventory	−7	−4	−1	−362,000	−3
Accounts receivable, net	−13	−5	−3	−987,000	−5
Prepaid expenses and other current assets	−6	1	820,000	−4	−4
Other non-current assets	−5	1	702,000	−1	−1
Accounts payable and accrued expenses	286,000	11	4	281,000	2
Employee related accrued expenses	3	−244,000	3	1	−3
Other current liabilities	−202,000	200,000	0	−703,000	47,000
Lease liabilities	−639,000	−1	−987,000	−1	−1
Restricted deposit	−1,000	49,000	0	—	—
Uncertain tax positions	112,000	597,000	176,000	176,000	125,000
Net cash used in operating activities	−162	−97	−76	−88	−85
Purchases of marketable securities	−77	−128	−50	−63	−52
Maturities of marketable securities	139	108	49	64	54
Purchases of property and equipment	−289,000	−295,000	−194,000	−254,000	−752,000
Net cash provided by (used in) investing activities	62	−21	−953,000	1	4
Principal payments on finance leases	−2	0	—	—	—
Proceeds from exercise of options into ordinary shares	2	321,000	873,000	2	61,000
Proceeds from issuance of long-term debt, net of issuance costs	0	24	0	96	0
Proceeds from pre-funded warrant issuance, net of issuance costs	0	19	49	0	—
Proceeds from ordinary shares issuances, net of issuance costs	40	151	67	0	0
Net cash provided by financing activities	40	195	117	97	72
Increase (Decrease) in Cash and Cash Equivalents	−61	77	40	11	−9
Right-of-use assets obtained in exchange for new operating and finance lease liabilities	7	2	122,000	2	−36,000
Acquisitions of IPR&D	3	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is UroGen Pharma Ltd.'s CIK number?

UroGen Pharma Ltd.'s SEC CIK number is 0001668243 (1668243). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find UroGen Pharma Ltd.'s SEC filings?

All of UroGen Pharma Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did UroGen Pharma Ltd. last report earnings?

UroGen Pharma Ltd. (URGN) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-015018). This is UroGen Pharma Ltd.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is UroGen Pharma Ltd.'s most recent earnings 8-K?

UroGen Pharma Ltd.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001437749-26-015018. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View UroGen Pharma Ltd.'s latest earnings 8-K →
Look up any company's CIK number →